Drugs / Ontuxizumab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01748721 | Nov 2013 → May 2015 | Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, T-cell large granular lymphocyte leukemia +23 | Morphotek | Completed | No outcome recorded |
| Phase 1 | NCT01773434 | Dec 2012 → Jul 2016 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00847054 | Mar 2009 → Apr 2014 | cancer | Morphotek | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT01574716 | Aug 2012 → Aug 2015 | soft tissue sarcoma | Morphotek | Completed | Missed primary |
| Phase 2 | NCT01335009 | May 2011 → Dec 2013 | metastatic melanoma | Eisai Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01507545 Comparator | Mar 2012 → Oct 2013 | colorectal cancer | Morphotek | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ontuxizumab | “Ontuxizumab is a humanized IgG monoclonal antibody that targets the cell-surface glycoprotein endosialin (tumor endothelial marker-1[TEM-1]/CD248) found on activated...” PMID 29292843 ↗ Jan 20181“A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic...” PMID 31034598 ↗ Apr 2019 |
| Known as | MORAb-004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01507545 ↗ |
| Known as | Ontecizumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364659 ↗ |
| Action | Inhibit | “block specific TEM-1 receptor-ligand interactions” NCT01507545 ↗ |
| Modality | Monoclonal antibody | “MORAb-004, a Humanized Monoclonal Antibody” NCT00847054 ↗ |
| Route | Intravenous | “Intravenous administration” NCT00847054 ↗ |
| Target | CD248 | “targets endosialin (tumor endothelial marker 1 [TEM-1] or CD248)” PMID 31034598 ↗ Apr 2019 |